The genus Mycobacterium contains several slow-growing human pathogens, including
Mycobacterium tuberculosis, Mycobacterium leprae, and Mycobacterium avium …

Mycobacteriophages show promise as therapeutic agents for non-tuberculous
mycobacterium infections. However, little is known about phage recognition of …

Mycobacterium abscessus is an emerging pathogen causing lung infection predominantly in
patients with underlying structural abnormalities or lung disease and is resistant to most …

Mycobacterium abscessus (MAB) infections pose a growing public health threat. Here, we
assessed the in vitro activity of the boronic acid-based β-lactamase inhibitor, vaborbactam …

Beta-lactams have been excluded from tuberculosis therapy due to the intrinsic resistance of
Mycobacterium tuberculosis (Mtb) to this antibiotic class, usually attributed to a potent beta …

Mycobacterium abscessus (Mab), an emerging opportunistic pathogen, predominantly
infects individuals with underlying pulmonary diseases such as cystic fibrosis (CF). Current …

Mycobacterium abscessus (Mabs) is an emerging nontuberculosis mycobacterial (NTM)
pathogen responsible for a wide variety of respiratory and cutaneous infections that are …

Mycobacterium abscessus (Mab) is a highly drug-resistant non-tuberculous mycobacterial
species that causes debilitating TB-like pulmonary infections. The lack of genetic tools has …

Mycobacterium tuberculosis (Mtb), perhaps more than any other organism, is intrinsically
appealing to chemical biologists. Not only does the cell envelope feature one of the most …

Mycobacterium abscessus (Mab) presents significant clinical challenges. This study
evaluated the synergistic effects of a β-lactam and β-lactamase inhibitor combination against …